Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies.
Standard
Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies. / Leeuwen, van; Kölble, Konrad; Huland, Hartwig; Huland, Hartwig; Hambrock, Thomas; Barentsz, Jelle; Schröder, Fritz H.
In: EUR UROL, Vol. 59, No. 2, 2, 2011, p. 183-190.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies.
AU - Leeuwen, van
AU - Kölble, Konrad
AU - Huland, Hartwig
AU - Huland, Hartwig
AU - Hambrock, Thomas
AU - Barentsz, Jelle
AU - Schröder, Fritz H
PY - 2011
Y1 - 2011
N2 - We addressed the question whether the change of serum prostate-specific antigen (PSA) in men who use 5?-reductase inhibitor (5-ARI) dutasteride is sensitive for the detection of aggressive prostate cancer (PCa).
AB - We addressed the question whether the change of serum prostate-specific antigen (PSA) in men who use 5?-reductase inhibitor (5-ARI) dutasteride is sensitive for the detection of aggressive prostate cancer (PCa).
KW - Biopsy
KW - Humans
KW - Male
KW - Risk Factors
KW - Prostate-Specific Antigen/blood
KW - 5-alpha Reductase Inhibitors/therapeutic use
KW - Azasteroids/therapeutic use
KW - Prostatic Neoplasms/drug therapy/epidemiology/pathology
KW - Biopsy
KW - Humans
KW - Male
KW - Risk Factors
KW - Prostate-Specific Antigen/blood
KW - 5-alpha Reductase Inhibitors/therapeutic use
KW - Azasteroids/therapeutic use
KW - Prostatic Neoplasms/drug therapy/epidemiology/pathology
M3 - SCORING: Journal article
VL - 59
SP - 183
EP - 190
JO - EUR UROL
JF - EUR UROL
SN - 0302-2838
IS - 2
M1 - 2
ER -